Global

‡ In these countries please contact our distributor

Smith & Nephew’s Episode of Care Assurance Program (eCAP) reduces hospital readmission by 97% following total joint replacement surgery

18 January 2018

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announces results showing a 97.3% decrease in readmission rates for joint arthroplasties (TJA) conducted under its Episode of Care Assurance Program (eCAP).

Working with Provider PPI, eCAP combines Smith & Nephew’s leading hip and knee implants with its PICO™ Negative Pressure Wound Therapy and ACTICOAT™ Flex 7 Antimicrobial Barrier Dressings. These products are applied post-surgery; PICO may help protect the incision by reducing seroma and hematoma fluid collections, reducing edema and lateral tension and improving perfusion.1-5 ACTICOAT Flex 7, which contains Nanocrystalline Silver, provides an effective barrier to microbial contamination to help deter surgical site infections.6

Over the past 14 months 1,380 TJAs have been conducted under the eCAP program with only two readmissions, a readmission rate of only 0.145% as compared to published rates of 5.3% or more.7 

“As healthcare systems move from fee for service to pay for value, healthcare providers are increasingly responsible for the episode of care for the patient,” said Glenn Warner, President Smith & Nephew US. “eCAP can help enable providers to reduce costly readmissions after TJA by adding class-leading wound care products to help manage surgical incisions. We are proud to support our customers with innovative programs that deliver improved care in a large-scale, real-world setting.”

Smith & Nephew worked with Provider PPI, a group purchasing organization, to implement this program at Provider PPI’s client facilities in late 2016 with positive results, and is now serving 16 facilities across the US.

“Adding PICO and Acticoat products from Smith & Nephew to our TJA cases has been a great win for our health system clients and their patients,” said Paul Gallagher, Vice President, Provider PPI. “I am extremely pleased to see our readmission rate drop to nearly zero. In Smith & Nephew we’ve worked with a comprehensive product solutions partner that’s willing to stand behind its product portfolio.”

Enquiries

Media

 

Charles Reynolds

+44 (0) 1923 477314

Smith & Nephew

 

Dave Snyder

+1 (978) 749-1440

Smith & Nephew

 

Simon Conway / Debbie Scott

+44 (0) 20 3727 1000

FTI Consulting

 

Investors  
Ingeborg Øie +44 (0) 20 7960 2285
Smith & Nephew

References

1. Lumb H. Bacterial barrier testing (wet-wet) of PICO™ dressing with a 7 day test duration against S.marcescens.
2. Wilkes RP, et al. Closed incision management with negative pressure wound therapy (CIM):Biomechanics. Surg Innov 2011.
3. Karlakki S, et al. Negative Pressure Wound Therapy for management of the surgical incision inm Orthopedic surgery. A review of evidence and mechanisms for an emerging indication. Bone Joint Res 2013; 2: 276-284.
4. Canonico S, et al. Therapeutic possibilities with portable NPWT. Initial multidisciplinary observations with the negative pressure device. Acta Vulnol 2012; 10: 57-66. Hoeflok J et al. Pilot clinical evaluation of surgical site infections with a novel handheld fluorescence imaging device. Proceedings of the Annual Military Health System Research Symposium (MHSRS); 2014 Aug 18- 21; Fort Lauderdale, FL.
5. Selvaggi F, et al. New advances in Negative Pressure Wound Therapy (NPWT) for surgical wounds of patients affected with Crohn's Disease. Surg Tech Int 2014; XXIV: 83- 89.
6. Burrell et al. Efficacy of Silver-Coated Dressing as Bacterial Barriers in a Rodent Burn Sepsis Model, WOUNDS 1999; 11(4):64-71.
7. Unplanned Readmission After Total Joint Arthroplasty: Rates, Reasons, And Risk Factors - The Journal Of Bone & Joint Surgery - jbjs.org - Volume 95-A - Number 20 October 16, 2013.
For detailed product information, including indications for use, contraindications, effects, precautions and warnings, please consult each product’s Instructions for Use (IFU) prior to use.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office